SMYD5 and lung carcinoma: The common sites of lung cancer metastasis are bone, liver, brain, lymph nodes, and adrenal glands (Riihimaki et al., 2014). During anticancer treatment in lung cancer, to reduce the incidence of distant metastasis and micrometastasis, cotreatment with SMYD5-specific inhibitors and general anticancer drugs is needed.